Scopus Biopharma, Inc. is a biopharmaceutical company, which engages in the development of therapeutics targeting diseases with unmet medical needs. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2020-12-16. The firm is focused on the development of its immuno-oncology programs for treatment-resistant cancers. The Company’s Duet Platform relies on an immuno-oncology with a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while alleviating tumor immunosuppression to jump-start T cell-mediated immune responses. The Duet Platform is comprised of three bifunctional oligonucleotides that consists of a toll-like receptor 9 (TLR9) agonist linked with a signal transducer and activator of transcription 3 (STAT3) inhibitor, which include CpG-STAT3siRNA (DUET-01), CpG-STAT3ASO (DUET-02) and CpG-STAT3decoy (DUET-03). The firm is developing DUET-01 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma. DUET-02 is being developed for systemic delivery for treatment of solid tumors such as prostate or kidney cancers.
Follow-Up Questions
¿Qué tal es el rendimiento del precio de la acción SCPS?
El precio actual de SCPS es de $0.0003, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Scopus Biopharma Inc?
Scopus Biopharma Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Scopus Biopharma Inc?
La capitalización bursátil actual de Scopus Biopharma Inc es $12623.999999999998
¿Es Scopus Biopharma Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 3 analistas han realizado calificaciones de análisis para Scopus Biopharma Inc, incluyendo 2 fuerte compra, 4 compra, 1 mantener, 0 venta, y 2 fuerte venta
